Prostate cancer (PCa) is the second leading cause of cancer-related death in men in the United States (Greenlee et al, 2001 ) and also is a common cancer increasing in Japan (Yamamoto, 1999) . Current staging modalities in predicting locally advanced and metastatic PCa include serum prostate-specific antigen (sPSA) level, transrectal ultrasound (TRUS), computed tomography (CT) scan (Catalona et al, 1994) . PSA, which belongs to the tissue kallikrein family, is primary produced by the prostatic epithelium and the secretion is regulated by the androgen level (Webber et al, 1996) . PSA secretion is tissue specific, and elevated sPSA is an effective marker for identifying men who have PCa (Crawford et al, 1997) . However, it is also often elevated in men with benign prostatic hyperplasia (BPH), prostatitis and other non-malignant disorders (Crawford and DeAntoni, 1993) . Therefore, to obtain clinical diagnosis, prostate biopsy is performed. However, in other urological tumours like renal cell cancer (RCC), biopsy is not a common modality for diagnosis, since it might cause cancer cells dissemination into blood flow or surrounding tissues and contribute to disease progression (Smith, 1984; Kiser et al, 1986 ). This point is not negligible also when regarding prostate cancer, and the implication in biopsy and possible tumour dissemination needs to be investigated. Despite the clinicopathological stage of the disease in the patients with PCa, the frequency of detection of distant metastasis by routine clinical analysis is not concordant with the frequency of disease recurrence after definitive local therapy (Levine et al, 1986) .
Reverse transcription polymerase chain reaction (RT-PCR) is a sensitive and useful method for detecting the presence of a specific cell type such as those bearing tumour-specific mRNA. Recently, several studies reported the presence of PSA-mRNA bearing cells, most likely PCa cells, in the peripheral blood using RT-PCR. Their detection rates in PCa patients were reported as 0 ˜8 8% Fadlon and Hamdy, 1998; Berteau et al, 1999; de la Taille et al, 1999) . Although it has been reported that prostate massage, digital rectal examination and ejaculation raise sPSA levels to some extent (Yuan et al, 1992; Zisman et al, 1997) , the presence of PSA-mRNA-bearing cells in the peripheral blood following these events has been seldom reported. Furthermore, the higher frequency of PSA-mRNA-bearing cells in the peripheral blood was correlated with the extent of the disease (de la Taille et al, 1999; Mejean et al, 2000; Su et al, 2000) . Thus, the presence of PSA-mRNA-bearing cells in peripheral blood after biopsy might contribute to tumour progression leading to poorer prognosis. In the present study, we further examined the relationship between clinicopathological findings and those detected using nested RT-PCR in prostate cancer patient's peripheral blood.
MATERIALS AND METHODS

Patients and their clinicopathological characteristics
A total of 108 patients with serum PSA levels elevated more than 4.0 ng ml -1 were selected for this study. Patient characteristics are presented in Table 1 . Informed consent to perform the study was obtained from all patients. Systemic sextant prostate biopsy was performed using transrectal ultrasound between October, 1998 and April, 2000, and if a hypoechoic lesion or hypervascular lesion was seen, an additional directed biopsy was performed when 
Blood samples and total RNA extraction
Peripheral blood samples were obtained before and within 10 minutes after prostate biopsy. Total RNA was extracted from 1 ml of whole blood anticoagulated with EDTA using an SV total RNA isolation system (Promega, Madison, Wisconsin).
RT-PCR
Nested PCR using outer and inner primer sets were applied. The sequences used for external PSA 20-mer primers were obtained from GenBank and were selected for lowest homology with human kallikrein nucleotide sequences examined by BLAST search. Outer primers were previously reported to identify circulating prostate tumor cells in blood (Ferrari et al, 1997) . They were anchored in exon 3 at nucleotides 648-667 (5′-GATGACTCCAGCCAC-GACCT-3′) and in exon 5 at nucleotides 1357-1338 (5′-CACAGA-CACCCCATCCTATC-3′). The nested PSA 20-mer primers were designed to be anchored in exon 4 at nucleotides 860-879 (5′-GCAAGTTCACCCTGAGAAGG-3′) and in exon 5 at nucleotides 1315-1296 (5′-GATATGTCTCCAGGCATGGC-3′).
The first strand DNA was synthesized using a single strand cDNA synthesis kit (Boehringer Mannheim, Inc, Mannheim, Germany) according to the manufacturer's instructions. Resulting cDNA was amplified by nested PCR in a thermal cycler 9600 (Perkin-Elmer, Norwalk, Connecticut). We amended the RT-PCR methods reported previously (Saito et al, 1996; Ferrari et al, 1997) .
To control for RNA integrity and to determine the significance of a negative PCR assay, we performed an RT-PCR assay involving the product of the housekeeping gene beta-actin. A set of 20-mer primers anchored at nucleotides 416-435 (5′-GATAT-GTCTCCAGGCATGGC-3′) and nucleotides 859-840 (5′-GATATGTCTCCAGGCATGGC-3′) of the beta-actin cDNA was synthesized to amplify a fragment of 520 bp.
3 negative control reactions were included in the PSA PCR experiment -a reaction with no added cDNA and a reaction containing human female peripheral blood mononuclear cells cDNA and that of healthy young males. A reaction containing cDNA synthesized from RNA derived from a mixture of one LNCaP cell and 1 ml of whole peripheral blood served as a positive control in each experiment. Dilutions of LNCaP were prepared as follows. LNCaP cells were counted in a chamber, and 1000 and 100 cells were directly diluted in 1 ml of whole blood anticoagulated with EDTA. 100 cells were further subjected to serial dilutions to furnish 10 cells and 1 cell in 1 ml. To confirm the reproducibility of the procedure, it was repeated 5 times which demonstrated same results, one of which is represented in Figure 1 .
Sequencing
The PCR products were electrophoresed in agarose gel electrophoresis and stained with ethidium bromide to confirm the products were derived from PSA-mRNA, the nucleotide sequences of some PCR products were sequenced. Briefly, purified products from agarose gel using Suprec 01 DNA recovery tubes (Takara, Japan), were directly determined on an ABI Prism 310 Genetic Analyzer (Perkin Elmer Japan Applied Biosystems). Labeling was performed with an inner PCR primer and a BigDye Terminator RR Mix (Perkin Elmer Japan Applied Biosystems). Each sequence was verified in both the sense and antisense directions (data not shown).
Statistical analysis
Statistical comparisons were made using the Welch corrected t-test and χ 2 tests in StatView 5.0 software for a Macintosh computer. Survival curves were generated using the method of Kaplan and Meier, and differences between curves were evaluated using the log-rank test.
RESULTS
PSA RT-PCR analysis of peripheral blood samples
RNA was extracted from the peripheral blood of 119 patients before and after prostate biopsy. As a first step, beta-actin PCR assay was performed to evaluate RNA integrity. 11 cases were excluded because of degradation of RNA. RNA samples from 108 patients were examined using RT-PCR. PSA-mRNA was detected in 3 PCa but in no BPH cases before biopsy. In 37 cases (16 of 62 BPH cases (25.8%) and 21 of 46 PCa cases (45.7%), PSA-mRNA was detected only after biopsy. There was no case, in which PSAmRNA bearing cells were detected in peripheral blood before biopsy became undetectable after the biopsy. In Figure 2 , representative RT-PCR findings from 4 PCa patients and 2 BPH patients are shown. PSA PCR product bands both before and after the biopsy were observed in Pt. No. 1, and 26. Pathological diagnosis of these were PCa, both of which had distant metastases and elevated sPSA of 380 ng ml -1 and 376.8 ng ml -1
, respectively (Figure 2) .
Comparison of clinicopathological parameters and PSA RT-PCR assay findings
The 3 cases with detectable PSA-mRNA before biopsy were all PCa with extraprostatic disease (T3 or T4 and/or N1 and/or M1) and had higher sPSA levels and PSA density (PSAD) than the other 105 cases with negative RT-PCR assay (P < 0.001) ( Figure 3A , B).
The patients with positive PSA-mRNA after biopsy either likely had higher sPSA levels than those with negative mRNA (77.4 ng ml -1 versus 11.3 ng ml -1
, P < 0.05), or PSAD levels (1.72 ng ml -1 cm -3 versus 0.35 ng ml -1 cm -3
, P < 0.05) ( Figure 3C, D) . A significant difference between the proportion of positive PSA-mRNA among PCa cases (52.2%) and BPH cases (25.8%) was observed after biopsy, and this significance could also be observed between these 2 groups with gray zone sPSA (4.0-10.0 ng ml Table 2 . A significant difference between the proportion of positive PSA-mRNA among the PCa cases with extraprostatic disease (3 of 11 cases -27.3%) and organ confined disease (T1 or T2, N0, M0) (0%) was observed before biopsy (P < 0.01) ( Table 2 ), but other clinical tumour stages were not correlated with RT-PCR findings. Among 46 PCa patients, no correlation was observed between positivity of RT-PCR and pathological differentiation, grade or Gleason score, but positive PSA-mRNA cases had more cancer involved biopsy cores (mean 4.2) than negative PSAmRNA cases (mean 2.2) after biopsy, and the difference was significant (P < 0.001) ( Figure 5 ).
All 46 PCa patients were treated with combined androgen blockade following diagnostic procedures involving prostate biopsy, and 6 and 2 cases of these underwent radical prostatectomy and radiation therapy, respectively. 1 case with positive PSAmRNA after biopsy and 1 with negative mRNA, died of diseasespecific causes. Disease progressions showing new metastatic sites were identified in 5 cases with positive PSA-mRNA and one with negative mRNA with imaging such as CT or isotope bone scans. The disease progression-free survival rate was lower in the N0, M0 cases with positive PSA-mRNA after biopsy than in the N0, M0 cases with negative mRNA, however, the difference was not significant (Figure 6 ).
DISCUSSION
Recent studies showed tumour cells circulating in peripheral blood were observed in several cancers including RCC or breast cancer, and the consequence in disease staging or prognosis has been demonstrated (de la Taille et al 2000; Sabbatini et al 2000) . In the present study, PSA-mRNA-bearing cells circulating in peripheral blood before prostate biopsy were identified in 3 of 11 cases (27.3%) of PCa with extraprostatic disease. These findings suggest that detection of circulating prostate cells would enable molecular staging in patients with PCa. However, 8 cases with extraprostatic disease including 1 patient with clinical stage T4, N0, M0 and 1121 ng ml -1 of sPSA showed negative RT-PCR before biopsy. New strategies for accurate staging of the disease have been tried including flowcytometric detection of PSA-positive cells in peripheral blood (Eskola et al, 1994) . RT-PCR is the most sensitive method and applicable to the molecular staging Okegawa et al, 2000) . Moreno et al, first applied PCR technology to the identification of circulating PSA-mRNA signals in patients with metastatic PCa and demonstrated a sensitivity of 33% (Moreno et al, 1992) . Although detection rates of PSA-mRNA positive cells in peripheral blood of prostate cancer patients varied between 0 and 88%, with more accurate molecular biological techniques staging before surgery may be achieved. However, no standard RT-PCR procedure has been established for detecting PSA-mRNA-bearing cells in peripheral blood. The difference depends upon sample collection and fractionation, storage, reverse transcription and amplification.
The present RT-PCR detected the presence of PSA-mRNA in peripheral blood in 40 of 108 (37.0%) patients after sextant prostate biopsy using TRUS. Among them, 37 patients (34.3%) were negative for PSA RT-PCR before biopsy. Moreno et al, reported among 43 TRUS cases, 42 cases were negative before biopsy and 4 cases (9.5%) converted to a positive RT-PCR PSA findings . Although the present methods for sample collection and RNA extraction differed from those of Moreno et al, the possibility of tumour spreading by prostate biopsy appears to be greater than that of previous studies. Extraprostatic disease (n = 11) 3/11* 8/11 T3 (n = 2) 1/2 2/2 T4 (n = 1) 0/1 1/1 N1 and/or M1 (n = 8) 2/8 5/8
Total (n = 46) 3/46 24/46 *P < 0.01.
The present study showed that the detection rate of PSA-mRNA after biopsy was higher in those with elevated sPSA (P < 0.05) or PSAD (P < 0.05) indicating a higher likelihood of the presence of PCa. Indeed, the detection rate was higher in the PCa group (P < 0.01) and, the patients with more positive cores had more frequency of PSA-mRNA-bearing cells in peripheral blood (P < 0.001). This finding suggests that PSA-mRNA after biopsy might have a diagnostic value, and especially with higher volume cancer cases, prostate biopsy might scatter the prostate constructing cells or prostate cancer cells into the blood stream, which might contribute to micrometastasis. However, PSA-mRNA were detected in also non-PCa cases indicating the presence of PSA-mRNA does not necessarily mean the presence of prostate cancer cells in peripheral blood.
Implantation of tumour cells along the needle tract or dissemination in patients with cancer is a rare but potential complication following percutaneous needle biopsy, and was reported as chest wall implantation of lung cancer and breast cancer after fine needle aspiration biopsy (Voravud et al, 1992; Paik et al, 1994) , and also as tumour extension along a biopsy needle tract from RCC (Smith et al, 1984; Kiser et al, 1986) . However, it is still controversial whether surgical manipulation or biopsy of the prostate causes dissemination and/or micrometastasis of prostate cancer cells. RT-PCR is an extremely sensitive method to detect specific mRNAbearing cells in the blood stream. It can detect a single specific mRNA-bearing cell among 10-10 8 cells (Raj et al, 1998) . Some studies reported that at least 10 4 circulating tumour cells are required for metastasis (Liotta et al, 1976) . Moreover, only 0.01% of circulating cancer cells create a single metastasis (Fidler, 1990; Fadlon et al, 1996) . Thus, a correlation between prognosis and detection of cancer cells in blood after surgery or biopsy are needed to clarify their clinical significance. Although the clinicopathological background and tumour biological behaviour in patients in the current study varied, the PSA-mRNA positive group after biopsy demonstrated a tendency towards decreased disease progression-free survival, indicating PSA-mRNA in blood after biopsy might have a prognostic value of disease progression-free survival. A long observation period is required to draw a definite conclusion and another modality to improve the information such as quantitative RT-PCR appears to be necessary for estimating the correlation between the number of circulating prostate cells and the presence of metastases or further disease progression after the biopsy.
It is concluded that nested RT-PCR could detect tumour cells in peripheral blood with higher sensitivity prior to metastases, enabling molecular staging of the tumour. We have also demonstrated that TRUS prostate biopsy might disperse prostate cells into the blood stream especially in cases with high sPSA. The prognosis for patients with clinically localized PCa and a positive PSA RT-PCR is currently not known. Although a prospective study comparing with the clinical course is required, to avoid dissemination of the tumour cells a minimal number of core biopsies for clinically and firmly diagnosed PCa should be adequate. To estimate the significance of detection of PSA-mRNA-bearing cells in the peripheral blood for metastasis and survival, further studies are warranted. Follow-up time (months) Progression free survival rate, % Figure 6 Disease progression-free survival of N0, M0 cases categorized according to PSA-mRNA after prostate biopsy. s s: group with negative PSAmRNA after biopsy;: group with positive PSA-mRNA after biopsy
